Awakn Announces Shareholder Approval of Arrangement
TORONTO, CANADA, April 23 2025 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”), is pleased to announce that further to its press releases…
---
News
Awakn Provides Supplemental Disclosure in Connection with Proposed Plan of Arrangement
TORONTO, CANADA, April 11, 2025 – Further to its press release dated February 27, 2025 and its management information circular dated May 10, 2025 (the “Circular”), Awakn Life Sciences Corp….
Awakn Enters into Arrangement Agreement for the Acquisition of Awakn by Solvonis Therapeutics plc
TORONTO, CANADA, February 27, 2025 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”) a clinical-stage biotechnology company developing therapeutics for substance use and mental…
Awakn Life Sciences Provides Update on R&D Programs, Progressing Novel Therapeutics for Alcohol Use Disorder and PTSD
Toronto, Canada – January 28, 2025 – Awakn Life Sciences Corp. (CSE: AWKN, OTCPink: AWKNF, FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics for…
Awakn Announces Positive Outcome of Pre-IND Meeting with FDA for AWKN-002 in Alcohol Use Disorder
Toronto, Canada – January 20, 2025 – Awakn Life Sciences Corp. (CSE: AWKN, OTCPIN: AWKNF, FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company developing therapeutics for substance use…
Awakn Enters Into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) plc
TORONTO, CANADA, December 16, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”) a clinical-stage biotechnology company developing therapeutics for substance use and mental…
Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program
Toronto, Canada – December 11, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company developing therapeutics for substance use…
Awakn Announces Opening of Four Additional Awkn-001 Phase 3 Trial Sites
Toronto, Canada – October 22, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company developing therapeutics for substance use…
Awakn Partners with the University of Nottingham for In Vivo Testing of Aminoindane New Chemical Entity Pre-Clinical Program
Toronto, Canada – October 15, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company developing therapeutics for substance use…
Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity Pre-Clinical Program
Toronto, Canada – October, 04, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics for…
Awakn Announces Upsizing and Closing of Tranche of Private Placement Financing
TORONTO, CANADA, September 18, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”) a clinical-stage biotechnology company developing therapeutics for substance use and mental…
Awakn Announces Key Progress in Pre-clinical Program
Toronto, Canada, August 28, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, is pleased to…
Sign Up for Newsletter
MAIN OFFICE
Awakn Life Sciences Corp
301-217 Queen St. W
Toronto, Ontario M5V 0R2
Canada
© 2023 Awakn Life Sciences Corp | Privacy Policy | Disclaimer
// ABOUT US SUB NAV
// THERAPEUTIC FOCUS SUB NAV
// R&D SUB NAV
